Imipenem-cilastatin as initial therapy for febrile cancer patients

• DOI: 10.1128/aac.30.2.211
• Publication Date: 2012-06-28T00:04:52Z
• Authors: G P Bodey; M E Alvarez; P G Jones; K V Rolston; L Steelhammer; V Fainstein
• Keywords: Imipenem/cilastatin; Cilastatin

Imipenem-cilastatin was used to treat 79 febrile episodes in 71 cancer patients, most of whom had neutropenia. The overall response rate 67%, and 76% the 45 documented infections responded. rates for septicemias pneumonias were 62%, respectively. Only 1 17 caused by gram-negative bacilli failed respond this therapy. common side effects skin rash, nausea, diarrhea. Eight superinfections detected during